Session Type: ePosters
Session Title: ePosters
Authors(s): E. Frolova, L. Filippova, A. Uchevatkina, O. Shadrivova, Y. Borzova, N. Klimko, A. Taraskina, N. Vasilyeva
Authors Affiliations(s): North-Western State Medical University named after I.I. Mechnikov, Russian Federation
Background:
Invasive pulmonary aspergillosis (IPA) is the most common invasive fungal infection in haematological patients. The diagnosis of IPA remains challenging, making desirable the availability of new specific biomarkers. The use of pro-inflammatory markers such as pentraxin 3 (PTX3) and Interferon-gamma induced protein-10 (IP-10) may be useful in the diagnosis of IPA. The aim of this study was to analyze PTX3 and IP-10 in bronchoalveolar lavage fluid (BALF) in hematological patients with and without IPA.
Methods:This case-control analysis included 21 adult patients with probable/proven IPA (EORTC/MSG, 2019) and 21 matched controls without evidence of IPA, out of a pool of prospectively enrolled (2016-2019) adult patients with underlying haematological malignancies and suspected pulmonary infection. BALF samples were stored at −700C. PTX3 and IP-10 levels were measured in BALF supernatants by an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (R&D, USA).
Results:The median age of patients with probable/proven IPA was 56 years (19-74), the comparison group was 55 years (24-73). In both groups, the majority were patients with lymphomas − 62%, patients with acute leukemia − 33%, multiple myeloma − 5%.The median PTX3 level in BALF was significantly higher in patients with probable/proven IPA when compared to patients without evidence of IPA (659 pg/mL (72-1926) vs 64 pg/mL (20-346); p=0.004) and a trend towards an increase of IP-10 (52 pg/mL (5-526) vs 5 pg/mL (5-92); p=0.07).
Conclusions:Our study shows that pentraxin 3 measurements in bronchoalveolar lavage fluid may help to identify patients with IPA. In the future, it is necessary to study the polymorphisms of the pentraxin 3 gene associated with the risk of developing IPA.
Session Type: ePosters
Session Title: ePosters
Authors(s): E. Frolova, L. Filippova, A. Uchevatkina, O. Shadrivova, Y. Borzova, N. Klimko, A. Taraskina, N. Vasilyeva
Authors Affiliations(s): North-Western State Medical University named after I.I. Mechnikov, Russian Federation
Background:
Invasive pulmonary aspergillosis (IPA) is the most common invasive fungal infection in haematological patients. The diagnosis of IPA remains challenging, making desirable the availability of new specific biomarkers. The use of pro-inflammatory markers such as pentraxin 3 (PTX3) and Interferon-gamma induced protein-10 (IP-10) may be useful in the diagnosis of IPA. The aim of this study was to analyze PTX3 and IP-10 in bronchoalveolar lavage fluid (BALF) in hematological patients with and without IPA.
Methods:This case-control analysis included 21 adult patients with probable/proven IPA (EORTC/MSG, 2019) and 21 matched controls without evidence of IPA, out of a pool of prospectively enrolled (2016-2019) adult patients with underlying haematological malignancies and suspected pulmonary infection. BALF samples were stored at −700C. PTX3 and IP-10 levels were measured in BALF supernatants by an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (R&D, USA).
Results:The median age of patients with probable/proven IPA was 56 years (19-74), the comparison group was 55 years (24-73). In both groups, the majority were patients with lymphomas − 62%, patients with acute leukemia − 33%, multiple myeloma − 5%.The median PTX3 level in BALF was significantly higher in patients with probable/proven IPA when compared to patients without evidence of IPA (659 pg/mL (72-1926) vs 64 pg/mL (20-346); p=0.004) and a trend towards an increase of IP-10 (52 pg/mL (5-526) vs 5 pg/mL (5-92); p=0.07).
Conclusions:Our study shows that pentraxin 3 measurements in bronchoalveolar lavage fluid may help to identify patients with IPA. In the future, it is necessary to study the polymorphisms of the pentraxin 3 gene associated with the risk of developing IPA.
Session Type: ePosters
Session Title: ePosters
Authors(s): E. Frolova, L. Filippova, A. Uchevatkina, O. Shadrivova, Y. Borzova, N. Klimko, A. Taraskina, N. Vasilyeva
Authors Affiliations(s): North-Western State Medical University named after I.I. Mechnikov, Russian Federation
Background:
Invasive pulmonary aspergillosis (IPA) is the most common invasive fungal infection in haematological patients. The diagnosis of IPA remains challenging, making desirable the availability of new specific biomarkers. The use of pro-inflammatory markers such as pentraxin 3 (PTX3) and Interferon-gamma induced protein-10 (IP-10) may be useful in the diagnosis of IPA. The aim of this study was to analyze PTX3 and IP-10 in bronchoalveolar lavage fluid (BALF) in hematological patients with and without IPA.
Methods:This case-control analysis included 21 adult patients with probable/proven IPA (EORTC/MSG, 2019) and 21 matched controls without evidence of IPA, out of a pool of prospectively enrolled (2016-2019) adult patients with underlying haematological malignancies and suspected pulmonary infection. BALF samples were stored at −700C. PTX3 and IP-10 levels were measured in BALF supernatants by an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (R&D, USA).
Results:The median age of patients with probable/proven IPA was 56 years (19-74), the comparison group was 55 years (24-73). In both groups, the majority were patients with lymphomas − 62%, patients with acute leukemia − 33%, multiple myeloma − 5%.The median PTX3 level in BALF was significantly higher in patients with probable/proven IPA when compared to patients without evidence of IPA (659 pg/mL (72-1926) vs 64 pg/mL (20-346); p=0.004) and a trend towards an increase of IP-10 (52 pg/mL (5-526) vs 5 pg/mL (5-92); p=0.07).
Conclusions:Our study shows that pentraxin 3 measurements in bronchoalveolar lavage fluid may help to identify patients with IPA. In the future, it is necessary to study the polymorphisms of the pentraxin 3 gene associated with the risk of developing IPA.
Session Type: ePosters
Session Title: ePosters
Authors(s): E. Frolova, L. Filippova, A. Uchevatkina, O. Shadrivova, Y. Borzova, N. Klimko, A. Taraskina, N. Vasilyeva
Authors Affiliations(s): North-Western State Medical University named after I.I. Mechnikov, Russian Federation
Background:
Invasive pulmonary aspergillosis (IPA) is the most common invasive fungal infection in haematological patients. The diagnosis of IPA remains challenging, making desirable the availability of new specific biomarkers. The use of pro-inflammatory markers such as pentraxin 3 (PTX3) and Interferon-gamma induced protein-10 (IP-10) may be useful in the diagnosis of IPA. The aim of this study was to analyze PTX3 and IP-10 in bronchoalveolar lavage fluid (BALF) in hematological patients with and without IPA.
Methods:This case-control analysis included 21 adult patients with probable/proven IPA (EORTC/MSG, 2019) and 21 matched controls without evidence of IPA, out of a pool of prospectively enrolled (2016-2019) adult patients with underlying haematological malignancies and suspected pulmonary infection. BALF samples were stored at −700C. PTX3 and IP-10 levels were measured in BALF supernatants by an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (R&D, USA).
Results:The median age of patients with probable/proven IPA was 56 years (19-74), the comparison group was 55 years (24-73). In both groups, the majority were patients with lymphomas − 62%, patients with acute leukemia − 33%, multiple myeloma − 5%.The median PTX3 level in BALF was significantly higher in patients with probable/proven IPA when compared to patients without evidence of IPA (659 pg/mL (72-1926) vs 64 pg/mL (20-346); p=0.004) and a trend towards an increase of IP-10 (52 pg/mL (5-526) vs 5 pg/mL (5-92); p=0.07).
Conclusions:Our study shows that pentraxin 3 measurements in bronchoalveolar lavage fluid may help to identify patients with IPA. In the future, it is necessary to study the polymorphisms of the pentraxin 3 gene associated with the risk of developing IPA.